相关实验视频

Updated: Jul 16, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

帕尔博西克利布释放神经母细胞瘤细胞的潜在分化能力

Kirsty M Ferguson¹, Sarah L Gillen¹, Lewis Chaytor²

¹Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.

Developmental cell

|September 21, 2023

概括

CDK4/6抑制剂palbociclib促进神经母细胞细胞中神经元分化. 将palbociclib与视网酸结合使用可能会改善这种常见婴儿癌症患者的存活率.

科学领域:

在瘤学瘤学.
发展生物学发展生物学
分子生物学分子生物学

背景情况:

神经母细胞瘤是一种流行的儿科脑外固体瘤,起源于神经细胞.
针对瘤分化的治疗策略为治疗神经母细胞瘤提供了一个有希望的途径.
了解驱动神经母细胞瘤发展的分子机制对于有效治疗至关重要.

研究的目的:

为了研究CDK4/6抑制剂palbociclib对神经母细胞瘤分化的影响.
探索palbociclib在神经母细胞瘤治疗中与视网酸结合的潜力.
阐明与palbociclib诱导的分化相关的表观遗传和转录变化.

主要方法:

用palbociclib.lib治疗上腺神经母细胞瘤细胞.
评估表型和转录变化表明神经元分化.
使用神经母细胞瘤小鼠模型的体内研究.
结合疗法与网红酸的研究.

主要成果:

帕尔博西克利布抑制了增殖,并在神经母细胞细胞中诱导了显著的神经元分化.
帕尔博西克利布治疗建立了一个表观遗传程序,驱动成熟的神经元特征.
在体内,palbociclib显示显著抑制瘤生长.
结合治疗与视网氨酸重置致癌电路,抑制增殖和增强分化.

结论:

帕尔博西克利布被确定为增强神经母细胞瘤分化的一种强有力的药物.
与palbociclib和视网酸的联合治疗显示出改善患者结果的潜力.
准差异化途径代表了神经母细胞瘤的可行的治疗策略.

关键词:

CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 CDK4 在CDK6中使用CDK6.细胞循环中的细胞循环.不同化的差异化差异化.神经母细胞瘤的神经母细胞瘤这是palbocicliblib.网红酸是什么意思网红酸是什么意思

更多相关视频

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...